Safety and Efficacy of Insulin Aspart in Type 2 Diabetes
Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Japan. The aim of this trial is to investigate the safety and
efficacy of NovoRapid® (insulin aspart) as meal time insulin in subjects with type 2 diabetes
treated on a basal-bolus regimen with Neutral Protamine Hagedorn (NPH) human insulin.